SG11202002635RA - Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation - Google Patents

Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Info

Publication number
SG11202002635RA
SG11202002635RA SG11202002635RA SG11202002635RA SG11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA SG 11202002635R A SG11202002635R A SG 11202002635RA
Authority
SG
Singapore
Prior art keywords
isolating
cancer
cells
methods
specific mutation
Prior art date
Application number
SG11202002635RA
Inventor
Drew C Deniger
Steven A Rosenberg
Parisa Malekzadeh
Original Assignee
The United States Of America As Represented By The Secretary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America As Represented By The Secretary filed Critical The United States Of America As Represented By The Secretary
Publication of SG11202002635RA publication Critical patent/SG11202002635RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464448—Regulators of development
    • A61K39/46445—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/464451—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
SG11202002635RA 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation SG11202002635RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Publications (1)

Publication Number Publication Date
SG11202002635RA true SG11202002635RA (en) 2020-04-29

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202002635RA SG11202002635RA (en) 2017-09-29 2018-09-17 Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation

Country Status (10)

Country Link
US (1) US20200316121A1 (en)
EP (1) EP3688142A1 (en)
JP (1) JP7391015B2 (en)
KR (1) KR20200065026A (en)
CN (1) CN111344394A (en)
AU (1) AU2018342245A1 (en)
CA (1) CA3080274A1 (en)
IL (1) IL273516A (en)
SG (1) SG11202002635RA (en)
WO (1) WO2019067242A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE058957T2 (en) * 2016-12-08 2022-10-28 Immatics Biotechnologies Gmbh Novel t cell receptors and immune therapy using the same
DE102016123847B3 (en) * 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh New T cell receptors and their use in immunotherapy
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CN114341171A (en) * 2019-06-27 2022-04-12 美国卫生和人力服务部 T cell receptor recognizing R175H or Y220C mutations in P53
CN112390875B (en) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 High-affinity T cell receptor for identifying AFP
EP4077641A1 (en) 2019-12-20 2022-10-26 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
TW202227477A (en) * 2020-09-04 2022-07-16 美國衛生與公眾服務部 T cell receptors recognizing r273c or y220c mutations in p53
CN112301088B (en) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 Method for screening neoantigen or neoantigen coding sequence
CA3209732A1 (en) 2021-02-25 2022-09-01 Drew Caldwell DENIGER Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
JP2024509472A (en) * 2021-03-08 2024-03-01 大鵬薬品工業株式会社 Treatment of cancer in patients with co-occurring genetic alterations in FGFR2 and cancer driver genes
JP2024513843A (en) * 2021-03-31 2024-03-27 ザ・ジョンズ・ホプキンス・ユニバーシティー Methods and materials for targeting tumor antigens
AU2022268998A1 (en) * 2021-05-07 2023-12-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
IL309957A (en) 2021-07-14 2024-03-01 2Seventy Bio Inc Engineered t cell receptors fused to binding domains from antibodies
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
CN116970058B (en) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 Tumor neoantigen polypeptide aiming at TP53 gene R249S mutation and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679641A (en) * 1992-05-26 1997-10-21 Rijksuniversiteit Leiden Peptides of human P53 protein for use in human T cell response inducing compositions, and human P53 protein-specific cytotoxic t-lymphocytes
JPH0959175A (en) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd Anti-tumor immuno-activating agent
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US20170218042A1 (en) * 2014-10-02 2017-08-03 The United State of America, as represented by the Secretary, Department of Health and Human Service Methods of isolating t cell receptors having antigenic specificity for a cancer-specific mutation
EP3848456A1 (en) * 2014-10-02 2021-07-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
CA2964785A1 (en) * 2014-11-05 2016-05-12 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
CA2968399A1 (en) * 2014-11-26 2016-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated kras t cell receptors

Also Published As

Publication number Publication date
US20200316121A1 (en) 2020-10-08
CN111344394A (en) 2020-06-26
WO2019067242A1 (en) 2019-04-04
CA3080274A1 (en) 2019-04-04
JP2020534839A (en) 2020-12-03
JP7391015B2 (en) 2023-12-04
EP3688142A1 (en) 2020-08-05
IL273516A (en) 2020-05-31
AU2018342245A1 (en) 2020-04-16
KR20200065026A (en) 2020-06-08

Similar Documents

Publication Publication Date Title
IL273516A (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
IL280738A (en) Methods, kits and apparatus for expanding a population of cells
DK3200818T3 (en) METHODS FOR ISOLATING T-CELL RECEPTORS WITH ANTIGEN SPECIFICITY TOWARDS A CANCER-SPECIFIC MUTATION
HUE056387T2 (en) Method for inducing antigen specific cd8 positive t cells
EP3142842A4 (en) Method of separating waste material
EP3219791A4 (en) Method for induction of t cells from pluripotent stem cells
PT3481942T (en) Methods for culturing organoids
IL284690A (en) Process for preparing btk inhibitors
EP3154555A4 (en) Method of producing leukocytes using ptpn2 inhibition for adoptive cell transfer
HK1246345A1 (en) Methods of culturing a mammalian cell
EP3134735A4 (en) Methods of measuring antigen-specific t cells
HK1252635A1 (en) Methods of preparing a primary cell sample
PL3119575T3 (en) Process for making isolating strips
EP3244901A4 (en) Methods for isolation of platelets
EP3137209A4 (en) Functionalized support material and methods of making and using functionalized support material
GB201608060D0 (en) Method of culturing T cells
EP3465203A4 (en) Methods of immunotherapy
EP3095875A4 (en) Luterial and method for isolating and culturing same
SG11201609269TA (en) Method of culturing cells
IL272403A (en) Methods for lysis of cells within a sample
GB201416866D0 (en) Methods for providing a prognosis of pregnancy
AU2014901720A0 (en) Method of culturing cells
GB201413329D0 (en) Methods of obtaining islet cells
GB201408570D0 (en) Methods of obtaining islet cells
GB201510216D0 (en) Methods for providing a prognosis of pregnancy